A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults
Latest Information Update: 13 Feb 2023
At a glance
- Drugs V 116 (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 01 Feb 2023 Primary endpoint has been met (Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116), Results published in The Lancet Infectious Diseases
- 01 Feb 2023 Primary endpoint has been met (Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax23), according to Results published in The Lancet Infectious Diseases
- 01 Feb 2023 Results published in The Lancet Infectious Diseases